These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF Wang N; Wen J; Ren W; Wu Y; Deng C Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836 [TBL] [Abstract][Full Text] [Related]
6. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146 [TBL] [Abstract][Full Text] [Related]
7. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
8. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
10. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872 [TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442 [TBL] [Abstract][Full Text] [Related]
12. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Estrada-Bernal A; Chatterjee M; Haque SJ; Yang L; Morgan MA; Kotian S; Morrell D; Chakravarti A; Williams TM Cell Cycle; 2015; 14(23):3713-24. PubMed ID: 26505547 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942 [TBL] [Abstract][Full Text] [Related]
15. Disulfiram/Cu Kills and Sensitizes Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830 [No Abstract] [Full Text] [Related]
16. A Combinatorial Strategy for Targeting Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621 [TBL] [Abstract][Full Text] [Related]
17. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. Notarangelo T; Sisinni L; Trino S; Calice G; Simeon V; Landriscina M Cancer Lett; 2018 Oct; 433():147-155. PubMed ID: 29969659 [TBL] [Abstract][Full Text] [Related]
18. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways. Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892 [TBL] [Abstract][Full Text] [Related]
20. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf Wu PK; Hong SK; Park JI Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]